North Central Cancer Treatment Group (NCCTG) Biospecimen Resource

中北癌症治疗组 (NCCTG) 生物样本资源

• 批准号: 7990043
• 负责人: JAN C BUCKNER
• 金额: $ 87.28万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-17 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7990043
• 关键词: Body Fluids; Cancer Patient; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Collection; Commit; Communities; Community Clinical Oncology Program; Community Practice; Diagnosis; Diagnostic; Disease; Disease Progression; Education; Emerging Technologies; Enrollment; Information Systems; Laboratory Study; Leadership; Malignant Neoplasms; Marketing; Mission; North Central Cancer Treatment Group; Participant; Patients; Policies; Prevention approach; Procedures; Process; Qualifying; Quality of life; Research; Research Personnel; Resources; Retrieval; Role; Site; Specific qualifier value; Specimen; Systems Development; Testing; Translational Research; Treatment Protocols; Tumor Tissue; cancer care; cancer prevention; cancer therapy; community setting; improved; novel strategies; prognostic; response

DESCRIPTION (provided by applicant): The mission of the North Central Cancer Treatment Group (NCCTG) is to improve the duration and quality of life of cancer patients by performing high-quality clinical and translational research in the community setting. NCCTG was founded on the premise that cancer care in the U.S. occurs primarily in the community practice setting. Consequently, the community is the most appropriate venue for testing novel approaches to prevention, diagnosis, treatment, and symptomatic management of cancer. Since 2003, NCCTG has received more than 17,000 tumor tissue blocks from over 12,000 patients, and NCCTG has received over 38,000 body fluid biospecimens from more than 9,500 patients. Typically, specimens are received from 70 to 90% of patients from whom they are requested, and approximately 75% originate from community oncology sites. Consequently, specimens representative of the clinical trial participants are available in sufficient numbers to answer the scientific questions posed in the correlative laboratory studies. The NCCTG Biospecimen Resource will support the NCCTG mission by providing superior biospecimens from patients enrolled on NCCTG trials that 1) are fully and consistently annotated, 2) have been collected under optimized standard conditions, 3) have undergone quality assessment, and 4) are stored under controlled conditions allowing efficient retrieval for distribution to qualified researchers. The four specific aims of this application are: 1) to continue to optimize the collection and annotation of biospecimens obtained from patients enrolled on NCCTG and other cooperative group clinical trials; 2) to maintain standard operating procedures (SOPs) for collecting, processing and storing biospecimens; 3) to apply emerging technologies for collection and processing of biospecimens; and 4) to provide ongoing oversight to the resource and Improve marketing and education regarding access to the resource for the research community. NCCTG representatives will actively participate in Group Banking Committee (GBC) activities, will assume leadership roles within the GBC as appropriate, and will implement policies established by the GBC. NCCTG is committed to harmonization of GBC processes, including standard operating procedures, promotion of the resource, information systems, and development of new strategies during the proposed RELEVANCE: The NCCTG Biospecimen Resource provides large numbers of well-annotated biospecimens from patients enrolled in specified treatment protocols with definitive endpoints, thus, enabling research in markers diagnostic of a particular disease entity, prognostic of disease progression or predictive of response to treatment. Appropriate and efficient use of this resource is vital to promote the scientific mission of NCCTG, other cooperative groups, and the national research agenda for cancer prevention and treatment.

描述（由申请人提供）：北中央癌症治疗组（NCCTG）的任务是通过在社区环境中进行高质量的临床和转化研究来改善癌症患者的持续时间和质量。 NCCTG建立在美国的前提下，主要发生在社区实践环境中。因此，社区是测试癌症预防，诊断，治疗和症状治疗的新方法的最合适的场所。自2003年以来，NCCTG已从12,000多名患者中收到了17,000多个肿瘤组织块，NCCTG已从9,500多名患者中收到38,000多名体液生物素。通常，从70％到90％的患者收到标本，约有75％来自社区肿瘤学位。因此，代表临床试验参与者的标本有足够的数量来回答相关实验室研究中提出的科学问题。 NCCTG Biospecimen资源将通过提供NCCTG试验的患者的出色生物测量来支持NCCTG任务，而NCCTG试验的患者完全稳定地注释，2）在优化的标准条件下收集了2），3）经过质量评估，4）进行了4）。在受控条件下，可以有效检索到合格的研究人员。本应用的四个具体目的是：1）继续优化从参加NCCTG和其他合作组临床试验的患者获得的生物测量的收集和注释； 2）维护用于收集，加工和存储生物测量的标准操作程序（SOP）； 3）应用新兴技术来收集和加工生物测量； 4）为了提供对资源的持续监督，并改善有关研究界资源访问的营销和教育。 NCCTG代表将积极参与集团银行委员会（GBC）活动，将在GBC中扮演领导角色，并将执行GBC制定的政策。 NCCTG致力于协调GBC流程，包括标准操作程序，资源的促进，信息系统以及在拟议期间的新策略的制定 相关性：NCCTG Biospecimen Resources提供了大量批准的具有明确终点的特定治疗方案的患者的宣传良好的生物测量，因此，在标志物中诊断了特定疾病实体的研究，对疾病进展或预测治疗反应的预后进行了诊断。适当有效地利用此资源对于促进NCCTG，其他合作组织和国家预防癌症预防和治疗的国家研究议程至关重要。